导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.99% | 3975/4773 |
| 近一周 | -3.19% | 3855/5462 |
| 近一月 | -3.23% | 1632/5421 |
| 近一季 | -1.95% | 1111/5209 |
| 近半年 | -5.42% | 2854/4920 |
| 近一年 | -16.31% | 3775/4366 |
| 近两年 | 30.47% | 2249/2954 |
| 近三年 | 10.65% | 1730/2253 |
| 成立以来 | 15.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.63% 4675/4961 |
8.71% 2556/5312 |
- - |
- - |
| 2025 | 3.42% 3123/4813 |
-6.78% 3396/3635 |
4.20% 832/4076 |
10.89% 3230/4524 |
-3.98% 3370/4813 |
| 2024 | 29.82% 122/3463 |
-4.77% 1763/2808 |
-8.28% 2205/3014 |
43.72% 8/3129 |
3.42% 823/3463 |
| 2023 | 3.77% 263/2656 |
3.89% 1099/2280 |
-2.90% 705/2385 |
7.56% 35/2515 |
-4.36% 979/2655 |
| 2022 | -25.25% 1299/2207 |
-17.91% 1280/1919 |
1.75% 1427/2016 |
-15.47% 1302/2113 |
5.88% 420/2208 |
| 2021 | -3.59% 916/1822 |
-14.48% 1177/1255 |
6.62% 733/1330 |
4.22% 373/1466 |
1.45% 929/1822 |
| 2020 | 20.95% 699/1250 |
-9.62% 698/1028 |
9.26% 800/1067 |
20.80% 49/1164 |
1.40% 1034/1184 |
| 2019 | 44.86% 163/1092 |
46.19% 18/739 |
-6.37% 499/788 |
-4.01% 756/850 |
10.25% 150/918 |
| 2018 | -23.02% 266/834 |
- - |
-14.94% 508/631 |
-2.71% 300/660 |
-1.07% 9/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证全指证券公司ETF联接C VS. 长安沪深300非周期A(740101) |